Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 185 Neoplasms 181 Carcinoma, Non-Small-Cell Lung 153 Prostatic Neoplasms 120 Colorectal Neoplasms 111 Lung Neoplasms 97 Ovarian Neoplasms 83 Neoplasm Metastasis 82 Multiple Myeloma 76 Pancreatic Neoplasms 75 Leukemia, Myeloid, Acute 65 Endometrial Neoplasms 52 Stomach Neoplasms 48 Squamous Cell Carcinoma of Head and Neck 47 Melanoma 47 Recurrence 46 Lymphoma 45 Hematologic Neoplasms 44 Glioblastoma 44 Carcinoma, Renal Cell 44 Brain Neoplasms 44 Carcinoma, Hepatocellular 42 Urinary Bladder Neoplasms 41 Precursor Cell Lymphoblastic Leukemia-Lymphoma 39 Lymphoma, Non-Hodgkin 39 Leukemia, Lymphocytic, Chronic, B-Cell 38 Triple Negative Breast Neoplasms 35 Glioma 35 Small Cell Lung Carcinoma 34 Sarcoma 34

Interventions

ribociclib 1 palbociclib 1 abemaciclib 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HR+/HER2- Breast Cancer × 30 days × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡